SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: The Effect of Androgen Deprivation Therapy With Enzalutamide on Bladder Cancer Chemoprevention

The Effect of Androgen Deprivation Therapy With Enzalutamide on Bladder Cancer Chemoprevention


  • Org Study ID: 52539
  • Secondary ID:
  • NCT ID: NCT02605863
  • NCT Alias:
  • Sponsor: University of Rochester - Other
  • Source: University of Rochester

Brief Summary

The purpose of this study is to examine the effect of androgen deprivation therapy through administration of enzalutamide on preventing bladder cancer recurrences in patients with non-muscle invasive bladder cancer (NMIBC).

Detailed Description


- A blood draw and an electrocardiogram (EKG). The blood draw will check levels of
testosterone, dihydro-testosterone, estradiol, and Vitamin D. Pre-study blood-work will
also include a complete blood count (CBC), basic metabolic panel (BMP/CHEM8) and liver
function test (LFT) if any of these labs were not drawn within 1 month prior to the
transurethral resection of bladder tumor (TURBT).

- Bladder tumor sample that is stored in the Department of Pathology will have additional
tests run on it to confirm study eligibility and to test for certain cell markers.

- After 1 month following the original TURBT, subjects will begin therapy with
enzalutamide. The study drug will be administered orally at a dose of 160mg daily for 12
months.

- Subjects will be monitored for adverse reactions or side effects from enzalutamide at
scheduled office visits.

- If the bladder tumor is classified as being intermediate risk", regularly scheduled
office visits will occur at 2 months post-operatively (i.e., 1 month after starting
enzalutamide), and then again at post-operative months 3, 6, 9 and 12, as is part of the
usual standard of care.

- If the bladder tumor is classified as being "high risk" and the subject receives BCG
therapy, then the office visits will occur on a slightly different schedule to conform
to the standard of care for this type of disease. Subjects in this group typically start
their intravesical BCG instillations 4-6 weeks post-operatively. Therefore, the subjects
will be seen approximately 1 month following the initial TURBT, and will begin therapy
with enzalutamide at that time, as described above. Subjects will be on study drug at
least 7 days prior to the initiation of BCG therapy, which will occur once a week for 6
weeks. Similar to the subjects in the intermediate risk group, the subjects receiving
BCG will also be seen 1 month after initiation of enzalutamide therapy to ensure there
are no adverse reactions to the study drug. Following this visit, they will be seen
again at the time of the post-BCG cystoscopy, which occurs 1 month after your 6th
instillation. Subjects will be seen again at the 3, 6, 9 and 12-month post-BCG
cystoscopy office visits, as part of routine care.

- Repeat blood work (CBC, BMP and LFTs) will be checked 1 month after starting
enzalutamide (approximately 2 months post-operatively). For subjects with intermediate
risk bladder cancer, these labs will be checked again at 3, 6, 9 and 12 months
post-operatively (as per the regularly scheduled office visits). For the high risk
patients receiving BCG therapy, these labs will be checked again at the 1, 3, 6 and
9-month post-BCG office visits (per the regularly scheduled office visits for these
patients).

- An EKG will be obtained at baseline (before starting the study drug), but will also be
re-checked at approximately 6 months (half-way through therapy with enzalutamide) to
ensure there are no signs of worsening cardiac disease while on the study drug.

- A cystoscopy will be done every 3 months as part of the standard of care for bladder
cancer follow-up. Lesions suspicious for tumor recurrence will be biopsied as per usual
standard of care. If a recurrence is documented, subjects will discontinue use of
enzalutamide.

- For subjects scheduled to undergo therapy with BCG, additional tests will be run on the
urine samples that subjects will already be providing in the Urology office as part of
the standard of care.

Overal Status Start Date Phase Study Type
Recruiting Start Date: January 2016 Phase 2 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Evaluate the recurrence rate in NMIBC subjects treated with Enzalutamide (androgen deprivation therapy)

Primary Outcome 1 - Time Frame: 1 year

Condition:

  • Bladder Cancer

Eligibility

Criteria:
Inclusion Criteria:

1. Subjects with histologically confirmed NMIBC who have undergone their TURBT.

2. Per the European Association of Urology (EAU) guidelines, only subjects with
Intermediate" or "High risk" bladder cancer will be enrolled21:

For patients with "high risk" bladder cancer, only those who undergo BCG therapy
following their TURBT will be eligible for enrollment.

3. Subjects who receive BCG instillations post-operatively will be eligible for
enrollment.

4. Subjects whose tumors are AR(+) as well as AR(-) will be included, but we will
restrict inclusion of AR(-) subjects so that they represent no more than 1/3 of the
total study population, or any single cohort (ie. the intermediate or high-risk
groups).

5. Subjects of child-bearing potential must agree to 2 acceptable forms of birth control.

Exclusion Criteria:

1. Subjects with "low risk" bladder cancer, as defined by the EAU guidelines21, will be
ineligible for enrollment.

2. Subjects with "high risk" bladder cancer who do not undergo BCG therapy following
their TURBT will be ineligible for enrollment.

3. Subjects who have "failed" BCG therapy in the past (had a recurrence of bladder cancer
despite prior use of BCG) will be ineligible for enrollment.

4. Subjects who receive an immediate post-TURBT single instillation of intravesical
chemotherapy will be ineligible for enrollment.

5. Subjects who receive a post-operative induction course of intravesical chemotherapy
(ie. more than just a single immediate post-operative dose of intravesical
chemotherapy) will be ineligible for enrollment.

6. Subjects who undergo blue-light/fluorescence cystoscopy will be ineligible for
enrollment.

7. Subjects with a history of heart attack within the previous 12 months or who have
unstable cardiovascular status will be ineligible for enrollment.

8. Subjects who have uncontrolled hypertension (for our purposes, defined as those having
a systolic blood pressure > 160 documented on 2 occasions despite appropriate medical
therapy) will similarly be ineligible.

9. Subjects with a history of venous thrombo-embolism (DVT/PE) within the past 3 years.

10. Subjects with a history of seizure disorders, or those with a history of stroke or
transient ischemic attacks (TIA) within the previous 12 months will be ineligible.

11. Subjects with a history of liver disease whose hepatic enzymes, alkaline phosphatase
or bilirubin are greater than twice the upper limit of normal will be ineligible.

12. Subjects with kidney disease with an estimated glomerular filtration rate (eGFR) < 30
will be ineligible.

13. Subjects with neutropenia will be ineligible.

14. Subjects with clinical hypogonadism, those on androgen replacement therapy, or those
with prostate cancer or other diseases treated with various forms of hormonal therapy
(not including 5-alpha reductase inhibitors) will also be ineligible for study
enrollment.

15. Subjects who have undergone therapy for any malignancy within the past 5 years except
for basal and squamous cell carcinomas of the skin will also be ineligible.

16. Subjects with prior histories of prostate cancer treated by definitive local therapy >
5 years ago will only be eligible if they have had no clinical or biochemical evidence
of recurrent prostate cancer.
Show More

Gender: Male

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Edward E. Messing, MD

Role: Principal Investigator

Affiliation: University of Rochester

Overall Contact

Name: Edward E. Messing, MD

Phone: 585-275-0998

Email: edward_messing@urmc.rochester.edu

Location

Facility Status Contact
University of Rochester
Rochester, New York 14642
United States
Recruiting Edward E. Messing, MD
585-275-0998
edward_messing@urmc.rochester.edu